|
|
||||||||
F508-CFTR) channel, the most common disease-associated mutation in cystic fibrosis, was abnormally low (a functional defect). To investigate the mechanism for the poor response of
F508-CFTR to cAMP stimulation, we examined, in excised inside-out patches, protein kinase A (PKA)-dependent phosphorylation activation and ATP-dependent gating of wild-type (WT) and
F508-CFTR channels expressed in NIH3T3 mouse fibroblasts.
F508-CFTR channel current also followed a sigmoidal function, but the rate of activation was at least 7-fold slower than that with WT channels. This result suggests that deletion of phenylalanine 508 causes attenuated PKA-dependent phosphorylation of the CFTR chloride channel.
F508-CFTR channels were maximally activated with PKA, the mutant channel and WT channel had indistinguishable steady-state Po values, ATP dose-response relationships and single-channel kinetics, indicating that
F508-CFTR is not defective in ATP-dependent gating.
F508-CFTR cell membrane. Our data showed that the estimated channel density for
F508-CFTR was
F508-CFTR is as important as the trafficking defect (a decrease in the number of functional channels in the plasma membrane) in cystic fibrosis pathogenesis.This article has been cited by other articles:
![]() |
J. Li, Y-Y. Xiang, L. Ye, L-C. Tsui, J. F. MacDonald, J. Hu, and W-Y. Lu Nonsteroidal anti-inflammatory drugs upregulate function of wild-type and mutant CFTR Eur. Respir. J., August 1, 2008; 32(2): 334 - 343. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. S. Ostedgaard, C. S. Rogers, Q. Dong, C. O. Randak, D. W. Vermeer, T. Rokhlina, P. H. Karp, and M. J. Welsh Processing and function of CFTR-{Delta}F508 are species-dependent PNAS, September 25, 2007; 104(39): 15370 - 15375. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Bompadre, Y. Sohma, M. Li, and T.-C. Hwang G551D and G1349D, Two CF-associated Mutations in the Signature Sequences of CFTR, Exhibit Distinct Gating Defects J. Gen. Physiol., March 26, 2007; 129(4): 285 - 298. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Bebok, J. F. Collawn, J. Wakefield, W. Parker, Y. Li, K. Varga, E. J. Sorscher, and J. P. Clancy Failure of cAMP agonists to activate rescued {Delta}F508 CFTR in CFBE41o- airway epithelial monolayers J. Physiol., December 1, 2005; 569(2): 601 - 615. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Liu, A. Veilleux, L. Zhang, A. Young, E. Kwok, F. Laliberte, C. Chung, M. R. Tota, D. Dube, R. W. Friesen, et al. Dynamic Activation of Cystic Fibrosis Transmembrane Conductance Regulator by Type 3 and Type 4D Phosphodiesterase Inhibitors J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 846 - 854. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Wang, G. Li, J. P. Clancy, and K. L. Kirk Activating Cystic Fibrosis Transmembrane Conductance Regulator Channels with Pore Blocker Analogs J. Biol. Chem., June 24, 2005; 280(25): 23622 - 23630. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Bompadre, T. Ai, J. H. Cho, X. Wang, Y. Sohma, M. Li, and T.-C. Hwang CFTR Gating I: Characterization of the ATP-dependent Gating of a Phosphorylation-independent CFTR Channel ({Delta}R-CFTR) J. Gen. Physiol., March 28, 2005; 125(4): 361 - 375. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. L. Clarke, L. R. Gawenis, T.-C. Hwang, N. M. Walker, D. B. Gruis, and E. M. Price A domain mimic increases {Delta}F508 CFTR trafficking and restores cAMP-stimulated anion secretion in cystic fibrosis epithelia Am J Physiol Cell Physiol, July 1, 2004; 287(1): C192 - C199. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ai, S. G. Bompadre, X. Wang, S. Hu, M. Li, and T.-C. Hwang Capsaicin Potentiates Wild-Type and Mutant Cystic Fibrosis Transmembrane Conductance Regulator Chloride-Channel Currents Mol. Pharmacol., June 1, 2004; 65(6): 1415 - 1426. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yang, A. A. Shelat, R. K. Guy, V. S. Gopinath, T. Ma, K. Du, G. L. Lukacs, A. Taddei, C. Folli, N. Pedemonte, et al. Nanomolar Affinity Small Molecule Correctors of Defective {Delta}F508-CFTR Chloride Channel Gating J. Biol. Chem., September 12, 2003; 278(37): 35079 - 35085. [Abstract] [Full Text] [PDF] |
||||
![]() |
A S Ramalho, S Beck, D Penque, T Gonska, H H Seydewitz, M Mall, and M D Amaral Transcript analysis of the cystic fibrosis splicing mutation 1525-1G>A shows use of multiple alternative splicing sites and suggests a putative role of exonic splicing enhancers J. Med. Genet., July 1, 2003; 40(7): e88 - 88. [Full Text] [PDF] |
||||
![]() |
A. C. V. deCarvalho, L. J. Gansheroff, and J. L. Teem Mutations in the Nucleotide Binding Domain 1 Signature Motif Region Rescue Processing and Functional Defects of Cystic Fibrosis Transmembrane Conductance Regulator Delta F508 J. Biol. Chem., September 20, 2002; 277(39): 35896 - 35905. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. V. J. Galietta, S. Jayaraman, and A. S. Verkman Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists Am J Physiol Cell Physiol, November 1, 2001; 281(5): C1734 - C1742. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. D. R. Setchell Soy Isoflavones--Benefits and Risks from Nature's Selective Estrogen Receptor Modulators (SERMs) J. Am. Coll. Nutr., October 1, 2001; 20(90005): 354S - 362. [Abstract] [Full Text] |
||||
![]() |
L. Al-Nakkash, S. Hu, M. Li, and T.-C. Hwang A Common Mechanism for Cystic Fibrosis Transmembrane Conductance Regulator Protein Activation by Genistein and Benzimidazolone Analogs J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 464 - 472. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |